Histidine decarboxylase inhibition: a novel approach towards the development of an effective and safe gastric anti-ulcer drug.
The involvement of histamine in mediating gastric function under normal and pathological conditions has been largely established. The relationship between gastric acid production and peptic ulcer diathesis is also well known. Recently, endogenous histamine formation and its release from mast cells has been implicated in the pathogenesis of human and experimental gastric ulcers produced by restraint and pyloric ligation. It has also been implicated in the gastric mucosal damage produced by drugs like aspirin, phenylbutazone and reserpine. These observations suggest that histidine decarboxylase inhibitors may be useful in the prevention of such lesions. Our studies on the evaluation of some histidine decarboxylase inhibitors show that these compounds have a promising potential for developing an effective and safe anti-ulcer drug. This mini-review incorporates the results of our studies which have been adequately supported by other studies as well.
D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002392:Catechin / Q000031:analogs & derivatives; D005419:Flavonoids / Q000378:metabolism / Q000494:pharmacology*; D005744:Gastric Acid / Q000378:metabolism; D006632:Histamine / Q000494:pharmacology; D006640:Histidine Decarboxylase / Q000037:antagonists & inhibitors*; D006801:Humans; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000209:etiology
D000897:Anti-Ulcer Agents; D005419:Flavonoids; C029339:meciadanol; D006632:Histamine; D002392:Catechin; D002262:Carboxy-Lyases; D006640:Histidine Decarboxylase